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• Prospective study on elective surgery in cirrhosis
• HVPG measurement prior to surgery, n = 140








































 Hepatic venous pressure gradient is a prognostic factor in
cirrhotic patients undergoing surgery.
 ASA class and the type of surgery are the other main
prognostic factors.
 Hepatic venous pressure gradient values >16 mmHg are
independently associated with higher mortality.
 Hepatic venous pressure gradient values 20 mmHg identify
the patients at highest risk.
 The potential of pre-surgery TIPS in high-risk patients
deserves further study.EnricReverter, Isabel Cirera, AgustínAlbillos,






The hepatic venous pressure gradient is
associated with outcomes in patients
with cirrhosis undergoing elective extra-
hepatic surgery. It enables a better strat-
ification of risk in these patients and
provides the foundations for potential
interventions to improve post-surgical
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Background & Aims: Surgery in cirrhosis is associated with a
high morbidity and mortality. Retrospectively reported
prognostic factors include emergency procedures, liver function
(MELD/Child-Pugh scores) and portal hypertension (assessed
by indirect markers). This study assessed the prognostic
role of hepatic venous pressure gradient (HVPG) and other
variables in elective extrahepatic surgery in patients with
cirrhosis.
Methods: A total of 140 patients with cirrhosis (Child-Pugh A/B/
C: 59/37/4%), who were due to have elective extrahepatic sur-
gery (121 abdominal; 9 cardiovascular/thoracic; 10 orthopedic
and others), were prospectively included in 4 centers (2002–
2011). Hepatic and systemic hemodynamics (HVPG, indocya-
nine green clearance, pulmonary artery catheterization) were
assessed prior to surgery, and clinical and laboratory data were
collected. Patients were followed-up for 1 year and mortality,
transplantation, morbidity and post-surgical decompensation
were studied.
Results: Ninety-day and 1-year mortality rates were 8% and
17%, respectively. Variables independently associated with
1-year mortality were ASA class (American Society of Anesthe-
siologists), high-risk surgery (defined as open abdominal and
cardiovascular/thoracic) and HVPG. These variables closely pre-
dicted 90-, 180- and 365-day mortality (C-statistic >0.8). HVPG
values >16 mmHg were independently associated with
mortality and values ≥20 mmHg identified a subgroup at very
high risk of death (44%). Twenty-four patients presented persis-
tent or de novo decompensation at 3 months. Low body mass
index, Child-Pugh class and high-risk surgery were associated
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with death or decompensation. No patient with HVPG
<10 mmHg or indocyanine green clearance >0.63 developed
decompensation.
Conclusions: ASA class, HVPG and high-risk surgery were prog-
nostic factors of 1-year mortality in cirrhotic patients undergo-
ing elective extrahepatic surgery. HVPG values >16 mmHg,
especially ≥20 mmHg, were associated with a high risk of
post-surgical mortality.
Lay summary: The hepatic venous pressure gradient is associ-
ated with outcomes in patients with cirrhosis undergoing elec-
tive extrahepatic surgery. It enables a better stratification of risk
in these patients and provides the foundations for potential
interventions to improve post-surgical outcomes.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. All rights reserved.
Introduction
Cirrhosis is a life-threatening condition and a major cause of
morbidity and mortality worldwide. Improvements in the man-
agement of its related complications, of its etiologies (i.e. viral
eradication), and the option of liver transplantation have
increased life expectancy of patients with cirrhosis. In this set-
ting, it is not unusual that major surgical procedures are pro-
posed for patients with cirrhosis to address orthopedic,
malignancy or cirrhosis related complications. In fact, patients
with cirrhosis have a high incidence of gallstones and abdomi-
nal wall hernias that require surgical repair.1–4 Surgery in cir-
rhosis has always been associated with high perioperative
morbidity (about 30%, including infections, renal failure, decom-
pensation, blood transfusion, re-intervention, etc.) and mortal-
ity, ranging from 10 to 30% in the most recent series.5–11 The
main factors associated with these poor outcomes have been
related to liver function (Child-Pugh or model for end-stage
liver disease [MELD] scores), to the type of surgery (higher risk
in open abdominal, cardiovascular and thoracic surgeries), and
to the presence of signs or symptoms of portal hypertension
(PHT).5,8,10–14 However, there are no universally accepted019 vol. xxx j xxx–xxx
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ever needed. Clinical and laboratory variables were collected
at month 6 and 12 after surgery.
obtain the baseline HVPG. Permanent tracings were obtained
in each case in a multichannel recorder (GE Healthcare, Milwau-
kee, WI).
Hepatic blood flow was measured by the Fick principle dur-
ing a continuous infusion of indocyanine green, as previously
described.22 Briefly, preceded by a priming dose (5 mg), a
solution of indocyanine green (Pulsion Medical Systems,
Munich, GE) was infused intravenously at a constant rate of
0.2 mg/min. After an equilibration period of at least 40 min, 4
separate sets of simultaneous 3 ml samples of peripheral and
hepatic venous blood were obtained for the measurement of
hepatic blood flow (HBF). Hepatic clearance of indocyanine
green, fractional clearance, and hepatic intrinsic clearance were
used as quantitative liver function tests.
Plasma renin activity was also studied as an index of effec-
tive hypovolemia. Systemic and pulmonary vascular resistance
indexes (dyns/cm5m2) were calculated as follows, respec-
tively: (mean arterial pressure – right atrial pressure
[mmHg])79.9/cardiac index [Lmin1m2] and (pulmonary
artery pressure – pulmonary capillary wedge pressure
[mmHg])79.9/cardiac index [Lmin1m2], respectively. Hepa-
tic sinusoidal resistance (HSR) was estimated as
HSR = HVPG  79.9/HBF.
Research Article Cirrhosisprospective scores to assess surgical risk for patients with cir-
rhosis. The most widely accepted score is probably that from
the Mayo Clinic, based on MELD, ASA class and age.11,15
Although it was developed in a very large cohort, this model
combines emergency and elective surgery, combining different
profiles of patients that may act as confounding factors (for
example, MELD score is usually higher in emergency surgery
patients). The major weakness of prognostic studies of surgery
in cirrhosis is their retrospective nature and the lack of prospec-
tive validation studies.
Development of PHT in cirrhosis is associated with marked
systemic and splanchnic hemodynamic disturbances that pro-
gress in parallel to cirrhosis and are of prognostic significance.16
These disturbances impact on cardiopulmonary and renal circu-
lation and may contribute to post-surgical complications.
Although PHT has been evaluated in several studies, it has
always been done by means of indirect signs (clinical, labora-
tory or imaging) such as the presence of splenomegaly, ascites,
encephalopathy, esophageal varices or a low platelet count.9,10
Although the presence of these signs in cirrhosis is unequivo-
cally associated with clinically significant PHT, it may also be
present in their absence.17,18 In addition, studies assessing the
prognostic value of PHT in the natural history of cirrhosis have
identified different risk thresholds. Indeed, most clinical events
occurring in cirrhosis are associated with the degree of PHT:
ascites and collateral formation for HVPG values ≥10 mmHg,
variceal bleeding when ≥12 mmHg, and worse prognosis if
≥20 mmHg for variceal bleeding.18 HVPG has an important
value for prognostic stratification in surgery for hepatocellular
carcinoma (HCC), but studies assessing its prognostic value in
extrahepatic surgery are lacking.18,19 In this regard, accurate
assessments of the severity of PHT and of liver function by
HVPG measurement and indocyanine green clearance, respec-
tively, might reveal more sensitive prognostic factors for post-
surgical morbidity and mortality in cirrhosis.19,20
The aim of the present study was to define the prognostic
role of HVPG and other variables in a prospective cohort of
patients with cirrhosis undergoing elective extrahepatic
surgery.
Patients and methods
The present study is a prospective multicenter cohort study
assessing the prognostic role of HVPG and of other variables
in extrahepatic surgery in cirrhosis. The study was conducted
in 4 university hospitals (Hospital Clinic-Barcelona, Hospital
del Mar-Barcelona, Hospital Ramón y Cajal-Madrid, and Hospi-
tal Molinette-Torino) with expertise in the field of cirrhosis
and in surgical procedures in these patients. Inclusion criteria
were: liver cirrhosis of any etiology; elective extrahepatic sur-
gery planned within 3 months and requiring regional or general
anesthesia; informed consent of the patient. The exclusion crite-
ria were as follows: emergent surgery; liver resection and portal
hypertension surgery; terminal hepatic or extrahepatic disease
with expected survival lower than 6 months. The study was
approved by the Ethics Committee for Clinical Investigation of
the Hospital Clinic (registry number 6/3/2002) as well as by
each participating hospital Ethics Committee’s. The study was
conducted following the principles of the Declaration of
Helsinki.
One hundred forty patients with cirrhosis planned for elec-
tive extrahepatic surgery were prospectively included between2 Journal of Hepatology 20
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laboratory data were collected, and patients were followed-up
for 1 year after surgery, or until death/transplantation, which-
ever occurred first. Within the 3 months prior to surgery,
patients underwent the HVPG measurement. During hospital-
ization for surgery, patients were closely monitored to register
clinical course, development of post-surgical complications
and mortality. Complications developed during hospitalization,
length of stay, blood product transfusion and supportive thera-
pies (mechanical ventilation, renal replacement therapy, etc.)
were registered. After discharge, patients were visited at
6 weeks, 3 months and every 3 months up to 1 year, or when-Hemodynamic studies
Within the 3 months prior to surgery, patients underwent a
hemodynamic study, which included the assessment of hepatic
and cardiopulmonary pressures and hepatic blood flow by infu-
sion of indocyanine green. The studies were performed in fast-
ing conditions, under local anesthesia with anxiolytic doses of
midazolam (0.01–0.02 mg/kg). All patients underwent standard
non-invasive monitoring by continuous display of heart rate,
pulse oximetry, and respiratory rate along with blood pressure
(5 min). The right jugular vein was canalized under ultrasono-
graphic guidance (SonoSite Inc, Bothell, WA) with an 8F catheter
introducer (Axcess; Maxxim Medical, Athens, TX) by Seldinger
technique. Initially, under fluoroscopic control a pulmonary
artery catheter (Edwards Lifesciences, LLC, CA) was used to
measure cardiopulmonary pressures and cardiac output. After
that, HVPG measurement was performed as previously
described.21 In brief, a 7F balloon-tipped catheter (‘‘Fogarty”
Edwards Lifesciences LLC, CA) was guided into the main right
or middle hepatic vein for measurements of wedged (occluded)
(WHVP) and free hepatic venous pressures (FHVP). The HVPG
results from the difference between WHVP and FHVP. The ade-
quacy of occlusion was checked by gentle injection of a small
amount of radiologic contrast medium after balloon inflation.
All measurements were taken by triplicate and averaged to19 vol. xxx j xxx–xxx
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Outcome measures
The primary endpoint of the study was to evaluate post-
operative mortality at 90 days and up to 1 year of follow-up.
Secondary endpoints were the development of post-surgical
complications during hospitalization and de novo or worsening
hepatic decompensation lasting beyond 3 months after surgery.
The following events were considered main post-surgical com-
plications: new or worsening acute kidney injury (increase of
creatinine >50% or above 1.5 mg/dl), post-surgery hemody-
namic instability (any hypotension in the first 24 h requiring
vasoactive drugs and/or volume expansion), post-surgical
bleeding requiring transfusion, hepatic encephalopathy,
infections (urinary, wound, respiratory, catheter, etc.),
re-intervention, intubation longer than 24 h, development of
distress respiratory syndrome, re-intubation, deep vein throm-
bosis or pulmonary embolism. Intensive care unit and hospital
length of stay were registered.
In previously compensated patients, de novo decompensa-
tion was defined as jaundice or ascites persisting beyond
90 days from surgery, as well as any post-surgical encephalopa-
thy, PHT-related bleeding or spontaneous bacterial peritonitis.
Mild ascites through drainages not requiring diuretics and not
persisting at day 90 was not considered. In previously decom-
pensated patients, decompensation was defined as any new
type of decompensation or worsening from baseline (i.e.
increased number of episodes/intensity of hepatic encephalopa-
thy, need for paracentesis or increased diuretic dose in patients
with previous ascites, new PHT-related bleeding).
The study of 90-day and 1-year transplant-free survival
(endpoint mortality or transplantation) was done by multivari-
able survival Cox regression analysis. To assess the performance
and accuracy of predictions, including the significant variables,
Harrell C-statistic (3, 6 and 12 months) and Akaike information
criterion (AIC) were calculated. Harrell C-statistic is a natural
extension of the AUROC curve in the context of censored data
in survival analysis with binary endpoints. AIC estimates the
JOURNAL 
OF HEPATOLOGYrelative quality of statistical models for a given data set based
on likelihoods, the preferred model being the one with the low-
est AIC value. Two sub-analyses were performed: i) in the
abdominal subgroup, which was predominant in our cohort
(121/140 patients); and ii) in the high-risk surgery group, which
accounted for the majority of events.
A competing-risk regression analysis (Fine and Gray method)
was performed to control for the potential bias of liver trans-
plantation. This approach was also used to further understand
and delineate the contribution of each prognostic variable
according to the specific cause of death at follow-up: liver or
non-liver-related death.
The analysis of persistent/de novo decompensation was per-
formed using the Student’s t test for parametric continuous
variables and the Wilcoxon rank sum test for non-parametric
continuous variables. Categorical variables were assessed by
the Chi-square test or the Fisher’s exact test where appropriate.
Three-month decompensation was analyzed both including or
not including mortality (considering death as the worst decom-
pensation). Multivariable analysis was performed by logistic
regression including variables with a p value <0.05 at univariate
analysis.
To optimize multivariable analysis, based on our cohort size
and on previous studies of surgical risk in cirrhosis, surgery
types were grouped into high-risk and low-risk procedures.
The high-risk group comprised cardiovascular, thoracic andJournal of Hepatology 20
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laparoscopic and abdominal wall surgeries, orthopedic and
others. Child-Pugh and MELD scores were not simultaneously
included at multivariable analysis due to their collinearity.
Quantitative variables were expressed as mean ± standard
deviation and categorical variables as n (%). Statistical signifi-
cance was established at a 2-tailed p value of less than 0.05.
Analysis was performed with IBM SPSS Statistics 20.0 package
(SPSS Inc., Chicago, IL); survival nomogram was built with R
(version 3.5.1) and competing-risk analysis was performed with
the command ‘‘UAB Competing Risks” developed by the Applied
Biostatistics Laboratory (Autonomous University of Barcelona).
Results
Study cohort, procedures and outcomes
Between July 2002 and June 2011, 140 patients undergoing
elective extrahepatic surgery were prospectively included
(Fig. 1). Table 1 shows patients’ baseline characteristics and
Table 2 details surgical information and short and long-term
outcomes. Two patients with transjugular intrahepatic por-
tosystemic shunt (TIPS) and 1 patient with surgical shunt were
included (bleeding indication years before surgery, portal gradi-
ent between 7.5–10 mmHg, 2 survived and 1 died at follow-up).
Median follow-up after surgery was 360 days and mortality or
transplantation at 90 days was 8% (11/140 patients) and 17%
at 1 year (24/140 patients: 21 deaths and 3 orthotopic liver
transplants [OLTs]).
90-day and 1-year follow-up mortality/OLT
Eleven patients died during the 90 days after surgery. ASA class
and high-risk surgery were significantly associated with 90-day
mortality while HVPG and right atrial pressure showed a trend
to statistical significance (p = 0.059, both). No further multivari-
able analysis was done due to the low number of events.
At 1-year follow-up, 21 patients died and 3 underwent OLT.
Variables associated with mortality/OLT were ASA class, high-
risk surgery, HVPG, intrinsic indocyanine green clearance, renin
activity, albumin, Child-Pugh score and previous decompensa-
July 2002-June 2011:
165 patients with cirrhosis planned
for elective extra-hepatic surgery 
8 patients:
  • 2 Surgery without HVPG
  • 6 No consent for HVPG study
157 patients:
HVPG + Swan-Ganz study
within 3 months prior to surgery 
Study cohort:
140 patients with cirrhosis
undergoing elective surgery
Prospective 1 year follow-up 
17 patients: 
  • 10 Procedures not done
  • 1 Emergency surgery
  • 1 Liver Tx before surgery
  • 4 No cirrhosis (biopsy)
  • 1 Death before surgery 
Fig. 1. Flowchart of the patients included in the study. HVPG, hepatic
venous pressure gradient.19 vol. xxx j xxx–xxx 3
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tion. At multivariable analysis ASA class (hazard ratio [HR] III vs.
II = 2.98; HR IV vs. II = 9.97; p = 0.008), high-risk surgery
(HR = 3.65; p = 0.006) and HVPG (HR = 1.14; p = 0.003)
Fig. 3 shows the modifying effect of HVPG on expected mortality
as adjusted by ASA and type of surgery. HVPG was therefore
Table 1. Baseline clinical and laboratory characteristics of patients in the
study (N = 140).
Characteristics
Age (years) 62 ± 8
Male gender, n (%) 92 (66)
Etiology alcohol/viral/others, n (%) 59 (42)/54 (39)/27 (19)
Previous decompensation, n (%) 84 (60)
Non-selective b-blockers, n (%) 51 (36)
Diuretics, n (%) 63 (45)
Hepatic venous pressure gradient (mmHg) 15.0 ± 5.4
HVPG ≥10 mmHg, n (%) 116 (83)
Child-Pugh class A/B/C, n (%) 83 (59)/51 (37)/6 (4)
TIPS or surgical shunt, n (%) 3 (2)
MELD score (UNOS) 11.1 ± 3.2
MELD-Na score 12.1 ± 4.1
Previous surgeries, n (%) 82 (59)
Charlson comorbidity index 5.0 ± 1.8
Malignancy, n (%) 63 (45)
ASA class II/III/IV, n (%) 43 (31)/85 (60)/12 (9)
Body mass index (kg/m2) 27.1 ± 6.2
Creatinine (mg/dl) 1.0 ± 0.3
Na (mEq/L) 138 ± 4.1
Bilirubin (mg/dl) 1.7 ± 1.6
ALT (U/L) 51 ± 57
AST (U/L) 61 ± 48
Albumin (g/L) 36.3 ± 6.4
Hemoglobin (g/L) 118 ± 28
Leucocyte (x109/L) 5.4 ± 2.4
Platelets (x1012/L) 119 ± 67
Prothrombin activity (%) 73 ± 15
INR 1.22 ± 0.23
Results presented as mean ± SD unless otherwise indicated.
ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists; AST,
aspartate aminotransferase; HVPG, hepatic venous pressure gradient; INR, inter-
national normalized ratio; MELD, model for end-stage liver disease; TIPS, tran-
sjugular intrahepatic portosystemic shunt; UNOS, United Network for Organ
Sharing.
Research Article Cirrhosisremained as independent prognostic factors (Table 3). When
assessing the accuracy of potential predictions by these vari-
ables, Harrell C-statistic was very satisfactory for predictions
at days 90, 180 and 365 (>0.85 for all, Table 4).
A predictive nomogram for post-surgical mortality
was created with these 3 variables (Fig. 2). Probabilities
of death at time ‘‘t” can be also estimated by the equation
P = 1  e(CBH(t)  exp(b(t))  RiskPoints). Risk Points for each patient
are calculated from Cox regression coefficients for prognostic
variables as follows: 0.013  HVPG + ASA class points (II = 0,
III = 1.092, IV = 2.3) + risky surgery points (No = 0, Yes = 1.296).
CBH(t) and b(t) are the cumulated baseline hazard and the score
coefficient estimated by the model fitted for time t. At the time
points 180 and 365 days, these values are: CBH(180) = 0.00093,
b(180) = 1.151; CBH(365) = -0.00508, b(365) = 1.
Although only 3 patients reached OLT instead of death, a fur-
ther competing-risk analysis was performed. Previously identi-
fied variables were again independently associated with 1-year
mortality: ASA class (sHR = 2.73; p = 0.005), high-risk surgery
(sHR = 6.24; p <0.001) and HVPG (sHR = 1.13; p = 0.019). Since
all 3 patients undergoing OLT were in the low-risk surgery
group, sHR for high-risk surgery was higher than that at Cox
regression.4 Journal of Hepatology 20
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Among events, 15 deaths were related to liver events, 6 deaths
were not related to liver events, and the indication of the 3
patients undergoing OLT was de novo HCC (they were analyzed
as non-liver-related events). When previously identified prog-
nostic variables were analyzed for the specific cause of death,
HVPG (sHR = 1.23; p = 0.001) and high-risk surgery
(sHR = 11.28; p <0.001) were associated with liver-related
events (n = 15). When analyzing not liver-related events, ASA
class (n = 9) was the only associated variable (sHR = 5.39;
p <0.001). Table S1 further details this analysis.
Severity of portal hypertension andmortality: high- and low-
risk thresholds
After identifying HVPG as a prognostic factor, we assessed the
potential existence of different thresholds of risk for HVPG.dichotomized and different cut-offs were studied at Cox regres-
sion along with ASA class and type of surgery. A significant
increase in mortality was found for HVPG values >16 mmHg
(HR >2.5). HVPG values ≥20 mmHg (HR 5.67, p <0.001) identi-
fied an especially high-risk group of patients: 14 of 32 patients
above this value died/required OLT during follow-up (Fig. 4).
This cut-off (≥20 mmHg) was the most efficient when construct-
ing a predictive model with ASA and type of surgery: it showed
a similar performance (lowest AIC, equal C-statistic) to that
shown by the continuous HVPG model (Table 4).
Abdominal and high-risk surgery sub-analysis
Among the 121 abdominal surgeries there were 54 laparoscopic
(23 colectomies, 20 cholecystectomies, 6 gastrectomies, 2
exploratory, 1 splenectomy, 1 nephrectomy and 1 ileal resec-
tion), 41 open abdominal and 26 abdominal wall procedures.
Mortality/OLT at 3 months and at 1-year were 7% (9/121) and
16% (19/121), respectively. Mortality was low among laparo-
scopic procedures: 0 events at 90 days, 1 death and 2 OLTs at
1 year. Survival analysis confirmed the previously reported
prognostic variables: ASA class (HR III vs. II = 2.44; IV vs.
II = 16.4; p = 0.002), open abdominal surgery (HR = 4.3;
p = 0.001) and HVPG (HR = 1.18, p = 0.001). The C-statistic for
predictions with these variables was 0.909, 0.895 and 0.840 at
days 90, 180 and 365, respectively (Table 4). In this subgroup,
an HVPG of 20 mmHg was again the most efficient threshold
to detect patients at very high risk. The performance of both
prognostic models with a continuous or dichotomous HVPG
(≥20 mmHg) were equivalent (Table 4).
Among the 50 patients in the high-risk surgery group (open
abdominal, cardiovascular/thoracic), 16 died during follow-up.
ASA class and HVPG were independent prognostic factors with
similar HR to the overall cohort: 3.3 (III vs. II) and 8.8 (IV vs.
II) for ASA (p = 0.016) and 1.13 (p = 0.05) for HVPG. An HVPG
≥20 mmHg was the most efficient cut-off, along with ASA (HR
6.06; p = 0.001). Fig. S1 shows the effects of very high-risk HVPG
and ASA class as stratified by type of surgery.
De novo or worsening decompensation at 3 months
At 3 months after surgery, 32 patients had at least 1 persistent
de novo or worsening decompensation. Twenty-two developed
ascites, 8 presented with hepatic encephalopathy, 3 sponta-
neous bacterial peritonitis, 2 variceal bleeding, and 8 of them
finally died within the 3-month period. Three additional19 vol. xxx j xxx–xxx
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patients died without previous decompensation (sudden death,
cardiogenic shock and massive hemoperitoneum). Overall, 35
patients reached the combined endpoint (death/decompensa-
tion), which was associated with body mass index (BMI), ASA
class, high-risk surgery, MELD, international normalized ratio,
albumin, Child-Pugh score, indocyanine green fractional clear-
ance and intrinsic clearance, HVPG, and pre-surgical decompen-
sation (Table S2). At multivariable analysis, a lower BMI, Child-
Pugh score and high-risk surgery were independently associ-
ated with 3-month death or decompensation. When entering
MELD (or MELD-Na) instead of Child-Pugh score, variables inde-
pendently associated with decompensation were BMI, high-risk
surgery and HVPG (p = 0.018).
Four of the 24 (17%) patients alive and decompensated at
3 months died during the posterior follow-up, while 9 of 105
patients (9%) died in the non-decompensated group
(p = 0.235). A time-dependent analysis of decompensation
was associated with other surgical complications and 8 patients
died in the first 90 days. At follow-up, only 3 of 9 living patients
persisted with renal dysfunction (creatinine values increase by
between 55–100% from baseline), but none required dialysis.
HVPG, intrinsic and fractional indocyanine green clearances
were specifically analyzed. All decompensated patients had
HVPG values ≥10 mmHg. However, at multivariable analysis
(along with Child-Pugh score, BMI and high-risk surgery), nei-
ther this nor other potential cut-offs were independently asso-
ciated with decompensation. Regarding indocyanine green-
derived values (available in 115 patients), an indocyanine green
fractional clearance equal or greater than 0.63 identified
patients (20/115) with no risk of decompensation (Youden
Index of 0.243). At multivariable analysis, this cut-off was an
independent predictor of decompensation along with Child-
Pugh score and BMI (p value = 0.004).
Discussion
The present prospective study shows for the first time the prog-
nostic impact of HVPG on extrahepatic surgery in cirrhosis.
Besides HVPG, other prognostic variables for post-surgical mor-
tality were ASA class and type of surgery (high vs. low risk),
which had previously been reported.6,11,23 Importantly, our
study is, to date, the first to specifically assess the impact of
PHT by prospectively performing HVPG measurements prior
to surgery. In previous studies, most of them retrospective,
PHT was indirectly defined by signs such as a low platelet count,
splenomegaly, varices, ascites or previous decompensa-
tion.6,10,12,24,25 Although these signs are highly predictive of
PHT, the contrary is not always true: more than 50% of compen-
sated patients with HVPG >10 mmHg may have no varices and
normal or almost normal platelet count.26 In our study, a
detailed assessment of HVPG clearly shows that the severity
of PHT plays a major prognostic role in cirrhotic patients under-
going surgery. A further dichotomous characterization of HVPG
allowed for the identification of relevant cut-offs, >16 mmHg
and ≥20 mmHg: patients within these values were at high and
very high risk of death, respectively. Along with HVPG, ASA class
and the type of surgery (high risk vs. low risk) were the other
prognostic variable repeatedly reported in previous studies. In
our cohort, these 3 variables showed a good post-surgical prog-
nostication and the prognostic nomogram proposed from our
data might set the frame for future studies. We finally per-
formed a specific cause of death analysis since patients both
died of liver-related events and of non-liver-related events. By
this approach, liver-related events were associated with HVPG
and surgery type while extrahepatic deaths were related to
ASA class. In this regard, ASA class behaves as a robust func-
tional comorbid scale, better than other scales (i.e. Charlson)
and overcomes relevant factors such as malignancy, at least
for 1-year outcomes.
The observed mortality in our study cohort was 8% and 17%
at 90 and 365 days, respectively, similar to other cohorts includ-
ing elective surgeries8,15 but lower than most published series,
which also include emergency procedures (13–27% at 30 days
5,6,9,11
Table 2. Surgical procedures, outcomes, decompensation, 90-day and 1-
year follow-up mortality.
Surgical procedures
Overall surgical time (minutes), median (IQR) 120 (115)
Open abdominal; n = 41 216 (120)
Laparoscopic abdominal; n = 54 105 (80)
Abdominal wall surgery; n = 26 74 (63)
Cardiovascular and thoracic; n = 9 210 (185)
Orthopedic (arthroplasty/fracture repair); n = 7 90 (50)
Others; n = 3 120 ()
General/locoregional anesthesia, n (%) 127 (91)/13
(9)
ICU admission, n (%) 36 (26)
ICU length-of-stay (days), median (IQR) 3 (4)
Patients receiving blood-derived products transfusion, n
(%)
61 (44)
Packed red blood cells (units), median (IQR); n = 52 2 (3)
Fresh frozen plasma (ml), median (IQR); n = 31 1,000 (500)
Platelets (pools), median (IQR); n = 25 2 (3)
Perioperative morbidity (any), n (%) 69 (49)
Perioperative hypotension, n (%) 25 (18)
Perioperative bleeding, n (%) 21 (15)
Perioperative respiratory failure, n (%) 10 (7)
Surgical reintervention, n (%) 4 (3)
Arrhythmia, n (%) 8 (6)
Acute kidney injury, n (%) 17 (12)
Ionic disturbances, n (%) 20 (14)
Wound infection, n (%) 8 (6)
Post-operative infection, n (%) 27 (19)
Persistent de novo/worsening 3-month decompensation, n
(%)
24 (17)
Ascites, n (%) 22 (16)
Encephalopathy, n (%) 8 (6)
Spontaneous bacterial peritonitis, n (%) 3 (2)
Variceal bleeding, n (%) 2 (1)
Post-operative hospital length-of-stay (days), median (IQR) 6 (9)
In-hospital mortality, n (%) 7 (5)
90-day mortality, n (%) 11 (8)
1-year mortality/OLT, n (%) 24 (18)
Post-operative follow-up (days), median (IQR) 360 (42)
ICU, intensive care unit; OLT, orthotopic liver transplant.
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OF HEPATOLOGYadjusted by ASA, high-risk surgery and HVPG found no associa-
tion with follow-up mortality (HR = 1.12; CI 0.34–3.62;
p = 0.855).
As an event associated with decompensated or complicated
cirrhosis, post-surgical acute kidney injury was present in 17
patients, 12 of whom had moderate-tense ascites (Table 2). AKIJournal of Hepatology 20
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https://doi.org/10.1016/j.jhep.2019.07.007and around 30% at 90 days). However, it must be noted
that in elective procedures it is probably more relevant to bal-
ance the benefit/ratio risk before surgery if there are alternative
strategies. Most of the surgical procedures were abdominal,
with a small proportion of other surgical procedures. This has
limited the possibility of a more precise risk assessment for each19 vol. xxx j xxx–xxx 5
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Table 3. Baseline variables associated with 1-year post-surgical mortality or transplantation.
Alive (n = 116) Death/OLT (n = 24) Univariate p value Multivariate p value
Age (years) 62 ± 10 61 ± 12 0.636
BMI (kg/m2) 27.5 ± 6.4 25.3 ± 4.7 0.087
ASA class II/III/IV (%) 35/61/4 8/58/34 <0.001 0.008
Charlson comorbidity index (%) 5.0 ± 1.8 5.2 ± 1.7 0.673
High-risk surgery (yes/no) (%) 29/71 67/33 <0.001 0.006
Malignancy (yes/no) (%) 44/56 50/50 0.562
Etiology alcohol/viral/others (%) 45/35/20 29/58/13 0.135
b-blockers (yes/no) (%) 38/62 29/71 0.398
RAP (mmHg) 6.3 ± 3.7 5.4 ± 3.0 0.220
PAP (mmHg) 17.9 ± 7.1 16.8 ± 5.7 0.520
PCP (mmHg) 10.9 ± 5.6 9.6 ± 6.0 0.320
Cardiac index (L/min/m2) 3.5 ± 0.9 3.6 ± 0.7 0.769
MAP (mmHg) 91 ± 11 87 ± 14 0.234
SVRI (dysec/cm5m2) 2064 ± 635 1850 ± 444 0.148
PVRI, (dysec/cm5m2) 172 ± 91 165 ± 69 0.759
HVPG (mmHg) 14.3 ± 5.1 18.4 ± 5.3 0.001 0.003
HVPG ≥10 mmHg (yes/no) 94/22 22/2 0.209
HVPG >16 mmHg (yes/no) 49/67 16/8 0.006 0.0016
HVPG ≥20 mmHg (yes/no) 18/98 14/10 <0.001 <0.001
Hepatic blood flow (ml/min)* 997 ± 480 799 ± 370 0.107
IG fractional clearance* 0.47 ± 0.2 0.45 ± 0.1 0.626
IGCl (ml/min)* 278 ± 145 209 ± 85 0.064
Intrinsic IGCl (ml/min)* 616 ± 399 390 ± 175 0.031 0.347
Plasma renin activity (ng/ml/h) 1.0 ± 1.5
Creatinine (mg/dl) 1.0 ± 0.3
Na (mEq/L) 138 ± 4
ALT (U/L) 53 ± 62
Bilirubin (mg/dl) 1.6 ± 1.6
Albumin (g/L) 36.9 ± 6.5
Hemoglobin (g/L) 120 ± 28
Leucocyte (109/ml) 5.4 ± 2.4
Platelet (1012/ml) 120 ± 69
INR 1.2 ± 0.2
MELD score (UNOS) 10.9 ± 3.3
MELD-Na score 12.7 ± 4.2
Child-Pugh score 6.3 ± 1.5
Prev. decompensation (yes/no) (%) 55/45
Results presented as mean ± SD unless otherwise indicated. *n = 115 patients.
ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists; HVPG, hep














Research Article Cirrhosisspecific subtype of surgery. Although data on elective surgery is
scarce, several studies showed that in an emergent basis,
cardiovascular surgery is associated with the highest mortality
risk, while orthopedic surgery may have an intermediate
risk.24,27–35 For this reason we decided to create a dichotomous
capillary pressure; RAP, right atrial pressure; SVRI, systemic vascular resistance index
Table 4. Prognostic accuracy for variables associated with 1-year post-surg
both presented with HVPG as a continuous variable and as a dichotomous va
Overall cohort (N = 140)
HR (95% CI) Per
Quantita
ASA class III: 2.98 (0.7–13.2)
IV: 9.97 (2.0–50.4)
C-statistic: 90
180 d, 0.897; 36
High-risk surgery 3.65 (1.4–9.3)
HVPG 1.14 (1.05–1.25)
Dichotom
ASA class III: 3.78 (0.9–16.8)
IV: 12.15 (2.4–61.4)
C-statistic: 90
180 d, 0.886; 36
High-risk surgery 3.57 (1.4–9.0)
HPVG ≥20 mmHg 5.67 (2.4–13.2)
AIC, Akaike information criterion; ASA, American Society of Anesthesiologists; HR, h6 Journal of Hepatology 20
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https://doi.org/10.1016/j.jhep.2019.07.007surgical category (high risk/low risk) based on studies where
orthopedic, laparoscopic and abdominal wall surgeries were
associated with a lower post-surgical mortality compared to
open abdominal or cardiovascular surgeries.10,11,23 It allowed
to weigh the type of surgery in the model without the need
1.9 ± 2.1 0.040 0.239
1.0 ± 0.3 0.573
139 ± 4 0.484
42 ± 27 0.363
2.1 ± 1.7 0.166
33.7 ± 5.5 0.035 0.727
108 ± 24 0.079
5.4 ± 2.4 0.917
116 ± 60 0.820
1.3 ± 0.1 0.438
11.8 ± 2.9 0.208
13.3 ± 3.8 0.494
7.3 ± 1.5 0.006 0.775
83/17 0.019 0.178
atic venous pressure gradient; IGCl, indocyanine green clearance; INR, international
e; OLT, orthotopic liver transplant; PAP, pulmonary artery pressure; PCP, pulmonary
VRI, pulmonary vascular resistance index; UNOS, United Network for Organ Sharing.
al mortality in overall cohort and abdominal surgery subgroup. Models are
ble (HVPG < or ≥20 mmHg).
Abdominal surgery (n = 121)






C-statistic: 90 d, 0.909;
180 d, 0.895; 365 d, 0.840







C-statistic: 90 d: 0.909;
180 d, 0.890; 365 d, 0.840
C: 193.3 3.43 (1.3–8.8) AIC: 150.8
6.37 (2.49–16.31)
ard ratio; HVPG, hepatic venous pressure gradient.19 vol. xxx j xxx–xxx
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high MELD or Child-Pugh scores, a fact that would explain the
vs. open abdominal surgeries cannot be done in our cohort since
approach for major abdominal surgery in cirrhosis whenever
1
Fig. 4. Effect (hazard ratios) of different HVPG cut-offs on post-surgical 1-
year mortality/OLT adjusted by ASA class and type of surgery. HVPG values
JOURNAL 
OF HEPATOLOGYfor a multi-categorical variable, with very small group sizes,
which would have resulted in a loss of statistical power. Further
supporting the rationale for such dichotomous categorization,
higher surgical times (221 vs. 107 min) and hospital length of
stay (10.5 vs. 5 days) were observed in the high-risk surgical
groups. To reinforce our findings, we also found the same inde-
pendent prognostic factors when evaluating the more homoge-
neous subgroup of patients undergoing abdominal surgery.
A prominent and curious finding of our study is that MELD
and Child-Pugh scores, the most used and validated scores in
cirrhosis,15,36,37 including the surgical scenario, were not inde-
pendent predictors of post-surgical mortality. This is especially
intriguing for the MELD score, since it has been a prognostic fac-
tor in many surgical studies, one of which provided the founda-
tion for one of the most widely used prognostic scores (Mayo
Clinic model).5,11,15 Etiology, also included in this score, was
not associated with prognosis nor other prognostic variables.
A potential role for etiology could be better defined in larger
studies. Regarding MELD, several factors may account for our
negative results. First, our study only includes elective surgery
and patients undergoing elective procedures are in more stable
conditions and have better liver score values than those needing
emergency surgery. Indeed, only 5% of the patients from our
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Fig. 2. Nomogram for 30-day, 90-day and 1-year post-surgical survival
predictions according to the prognostic variables ASA class, low/high-risk
surgery and HVPG. ASA, American Society of Anesthesiologists; HVPG,







































Fig. 3. Observed survival and modifying effects of HVPG adjusted by ASA
class and type of surgery. HVPG values >16 mmHg associated a significantly
higher risk of death and values ≥20 mmHg identified the most at-risk
patients. ASA, American Society of Anesthesiologists; HVPG, hepatic venous
pressure gradient.Journal of Hepatology 20
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Hepatic venous pressure gradient (≥X mmHg) 
High risk Low risk Very high risk was 11. Therefore, our cohort does not include patients with
>16 mmHg were independent prognostic factors and values ≥20 mmHg
identified very high-risk patients (14 events in 32 individuals). ASA, American
Society of Anesthesiologists; HVPG, hepatic venous pressure gradient; OLT,
orthotopic liver transplant.lower mortality in relation to previous studies including emer-
gency surgery with worse MELD and Child scores. In fact, in the
study by Teh et al., median MELD (not the United Network for
Organ Sharing model) was clearly higher in emergency than in
elective surgery: 12.2 vs. 7.9.11 Whether HVPG could also be
an independent prognostic factor in emergency surgery remains
open. Nevertheless, while HVPG can be easily measured prior to
elective surgeries, it would be much more difficult to measure
in the emergency setting.
Despite the initiation of the study many years ago, the partic-
ipating hospitals are referral centers with totally contemporary
surgical procedures. In this sense, a laparoscopic approach was
applied whenever possible with a higher proportion of laparo-
scopic than open abdominal procedures (54 laparoscopies vs.
41 open). Laparoscopic surgeries included procedures requiring
high expertise and outcomes in this subgroup were satisfactory
with no events at 3 months and 3 events at 1 year. These find-
ings are in accordance with previous studies reporting lower
risks of decompensation and death with a laparoscopic
approach.38–43 However, a proper comparison of laparoscopylaparoscopy was generally the preferred approach and open
procedures were used, including complex surgeries (urologic/
digestive), when laparoscopy was not feasible. Thus, despite
our data not being conclusive, they support the laparoscopicfeasible, ideally in experienced centers.
In addition to mortality, we planned the analysis of 3-month
persistent/worsening or de novo decompensation as a surrogate
marker of increased risk of death during follow-up, as previ-
ously demonstrated in surgery for hepatocellular carcinoma.19
By selecting the 3-month period in assessing decompensation,
we avoided the inclusion of patients with temporal ascites
through drainages in abdominal surgery, which has an
unknown clinical meaning. Factors independently associated
with 3-month decompensation were high-risk surgery,
Child-Pugh score and a lower BMI, reflecting the role of poor19 vol. xxx j xxx–xxx 7
re gradient in cirrhotic patients undergoing elective extrahepatic surgery. J Hepatol (2019),
Research Article Cirrhosisnutritional status on post-surgical outcomes. If entering MELD
or MELD-Na instead of Child-Pugh as liver scores, variables
associated with decompensation were BMI, type of surgery
and HVPG. It must be pointed out that no patients with a
Child-Pugh score of 5 (n = 45, mean HVPG 12.5 mmHg) had
3 months persistent decompensation. Further reinforcing the
relevance of preserved liver function as a protective factor
against decompensation, we found that in patients with indo-
cyanine green clearance data (115 of 140 patients), an indocya-
nine green fractional clearance >0.63 protected patients from
decompensation. Regarding HVPG, all patients presenting with
decompensation had HVPG ≥10 mmHg. Anyhow, in the current
study we were unable to demonstrate an association between
3-month persistent decompensation and future mortality. The
low number of deaths within a short follow-up period and the
strength of other prognostic variables (high-risk surgery, ASA
and HVPG), which in part correlate with decompensation, may
have diluted the impact of persistent decompensation on subse-
quent mortality.
Overall, the reported prognostic role of HVPG might be an
argument for pre-surgical intervention (i.e. TIPS placement).
Many uncontrolled retrospective studies have claimed that TIPS
has a role in pre-surgical conditioning in cirrhotic patients.44–48
It has been postulated to diminish morbidity and mortality by
decompressing the portal venous system. However, results are
inconsistent across studies and despite the evidence that PHT
plays a major role on post-surgical outcomes, potential risk
thresholds to define patients in whom this strategy might be
useful have not been defined. The present study provides con-
crete values from which studies on pre-surgical optimization
could be planned: HVPG values above 16 mmHg were indepen-
dent prognostic factors and values ≥20 mmHg identified an
especially high-risk population. Our findings and proposed
prognostic models (nomogram in Fig. 2) might even allow for
a re-analysis of previous series, to confirm outcomes in patients
with ‘‘risky” pre-surgical HVPG values and in whom TIPS were
placed before surgery. In this regard, we included 3 patients
with portosystemic shunts, since we aimed to assess the whole
spectrum of PHT in our cohort. This low number of patients did
not allow us to perform a sub-analysis, and even if these
patients were excluded results remained unaltered. Therefore,
the protective role of a pre-surgical TIPS remains open.
The present study has several limitations to point out. First,
although a sample of 140 patients is large for a prospective
cohort, external validation is desirable to strengthen our find-
ings. In fact, the planned sample target was to include 200
patients in a period of 3 years, but a lower rate of inclusion than
expected led us to finish the study with 140 patients. Prospec-
tive studies targeting HVPG ‘‘risky” populations (as defined by
HVPG >16 mmHg) should be designed to confirm our findings
and to assess the potential benefit of lowering PHT. Second,
despite inclusion of several types of surgery, most of them were
abdominal. Based on sample size and previous literature, the
classification of surgeries was simplified to low vs. high risk,
though a more detailed categorization (and refined analysis)
would be desirable in larger series. Third, the study period
was dilated up to 10 years because of a low inclusion rate. How-
ever, looking at the type of procedures performed (high propor-
tion of laparoscopy, for example), our cohort looks fully
representative of contemporary surgical cohorts. Finally, our
study only includes cirrhotic patients in whom elective surgery
was considered by the medical-surgical team. Therefore, our
8 Journal of Hepatology 20
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inant Child-Pugh class A and B) and our findings must be inter-
preted in this setting.
In conclusion, the present study provides evidence for the
prognostic role of HVPG for post-surgical mortality in cirrhosis.
HVPG values above 16 mmHg were independent prognostic fac-
tors for mortality. These findings provide the framework for
future studies assessing the potential role of pre-surgical TIPS
in highly selected patients.
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